周鑫,向定成,张金霞,阮云军,杨靓,龚志华,文艳飞,夏丽莎,曹志英

• 1:广州军区广州总医院心血管内科

摘要(Abstract)：

目的探讨在首次医疗接触时给予不同剂量阿托伐他汀对接受直接经皮冠状动脉介入治疗(primary percutaneous coronary intervention,PPCI)的急性ST段抬高心肌梗死(ST-segment elevation myocardial infarction,STEMI)患者梗死相关区域心肌灌注水平的影响。方法纳入118例行PPCI的STEMI患者,在首次医疗接触时给予单次不同剂量阿托伐他汀,随机分为A组(给予阿托伐他汀80 mg,30例)、B组(给予阿托伐他汀40 mg,28例)、C组(给予阿托伐他汀20 mg,30例)和D组(给予安慰剂,30例),而后立即行冠状动脉造影及PPCI,术后测量并记录冠状动脉TIMI血流分级、心肌灌注分级(myocardial blush grade,MBG)、术后90 min心电图ST段回落程度(ST-segment resolution,STR)。结果四组患者梗死相关血管术前或术后的TIMI血流分级、MBG分别比较,差异均无统计学意义(均P>0.05)。四组患者术后90 min STR值分别为:A组(55.77±30.55)%,B组(53.66±28.14)%,C组(50.48±24.91)%,D组(42.03±30.63)%,组间比较,差异均无统计学意义(F=1.324,P=0.270),但A组至D组STR值总体均数呈逐渐降低趋势。结论对于接受PPCI治疗的STEMI患者,在首次医疗接触时给予负荷剂量的阿托伐他汀进行预处理未能改善PCI术后的冠状动脉血流及心肌灌注水平。

关键词(KeyWords)： 阿托伐他汀;急性心肌梗死;经皮冠状动脉介入治疗;心肌灌注

Abstract:

Keywords:

基金项目(Foundation): 广州市科技计划专项(2014Y2-00068);; 广东省科技计划项目(2012B031800182);; 广东省科技计划重大项目(2012A080104020);; 广州市重点实验室建设专项(穗科信字[2013]163-15)

作者(Author): 周鑫,向定成,张金霞,阮云军,杨靓,龚志华,文艳飞,夏丽莎,曹志英

参考文献(References)：

• [1]杨平,余宏伟,魏彤.长期应用阿托伐他汀对溶栓治疗急性ST段抬高心肌梗死的心肌保护作用.山东医药,2012,52:42-43.
• [2]唐湘.阿托伐他汀对急性心肌梗死患者血浆高敏C-反应蛋白的作用及其对心功能的保护.中国当代医药,2010,17:44-45.
• [3]Pasceri V,Patti G,Nusca A,et al.Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention;results from the ARMYDA(Atorvastatin for Reduction of MYocardial Damage during Angioplasty)study.Circulation,2004,110:674-678.
• [4]Kim JS,Kim J,Choi D,et al.Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in STsegment elevation myocardial infarction:the STATIN STEMI trial.JACC Cardiovasc Interv,2010,3:332-339.
• [5]American College of Emergency Physicians,Society for Cardiovascular Angiography and Interventions,OGara PT,et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction;a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2013,61:e78-140.
• [6]LaRosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med,2005,352:1425-1435.
• [7]Cannon C,Braunwald E,McCabe C,et al.Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes(PROVE IT-TIMI 22).New Engl J Med,2004,350:1495-1504.
• [8]Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes;the MIRACL study:a randomized controlled trial.JAMA,2001,285:1711-1718.
• [9]Briguori C,Colombo A,Airoldi F,et al.Statin administration before percutaneous coronary intervention:impact on periprocedural myocardial infarction.Eur Heart J,2004,25:1822-1828.
• [10]Briguori C.Visconti G,Focaccio A,et al.Novel approaches for preventing or limiting events(Naples)II trial:impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.J Am Coll Cardiol,2009,54:2157-2163.
• [11]Patti G,Pasceri V,Colonna G,et al.Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention:results of the ARMYDA-ACS randomized trial.J Am Coll Cardiol,2007,49:1272-1278.
• [12]Zhao SP.Yu BL,Peng DQ,et al.The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China:Results of the CHILLAS trial.Atherosclerosis,2014,233:707-712.
• [13]Jang Y,Zhu J,Ge J,et al.Preloading with atorvastatin before percutaneous coronary intervention in statin-naive Asian patients with non-ST elevation aoute coronary syndromes:A randomized study.J Cardiol,2014,63:335-343.